DSIP Peptide: What the Research Actually Found

DSIP Peptide: What the Research Actually Found

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide isolated from rabbit blood in the 1970s. It is not approved by the FDA for any use. The human trial record spans roughly 1984 to 1992, involves sample sizes of 6 to 16, and the authors of the best-controlled study concluded that DSIP "is not likely to be of major therapeutic benefit" for chronic insomnia. Here is what the evidence actually says, and what the FDA did with it in July 2026.

Key Takeaways

• The substance the FDA calls emideltide is the same molecule online forums and videos call DSIP. An FDA advisory panel voted 6 to 7 against recommending it on July 24, 2026.
• The entire human trial base consists of a handful of small studies from the 1980s and early 1990s, with no modern controlled trial.
• The only double-blind trial (n=16) found weak objective improvements but no change in subjective sleep quality. Its authors said the result was unlikely to be of major therapeutic benefit.
• DSIP is not an FDA-approved drug, and products sold online are not dietary supplements under federal law.

The Name Nobody Connects: DSIP Is Emideltide

The FDA and its Pharmacy Compounding Advisory Committee use the name emideltide. Videos, forums, and grey-market product labels use DSIP. They are the same molecule. This matters because two entire bodies of writing, the regulatory coverage written for compounding pharmacies and the consumer peptide content, have never referenced each other. The STAT News report on the July 2026 vote names emideltide but not DSIP. The vendor pages name DSIP but not the vote. Connecting the two is the whole point of this page.

What DSIP Is, and Where It Came From

DSIP is a nonapeptide, meaning it is built from nine amino acids. It was isolated by the Schoenenberger and Monnier group in Basel from the cerebral venous blood of rabbits in an induced sleep state, first described in 1974. The peptide was originally believed to be involved in sleep regulation because it appeared to induce slow-wave sleep in rabbits, but as that same source notes, "studies on the subject have been contradictory."

DSIP has low molecular stability in vitro, with a half-life reported at about 15 minutes, attributed to a specific aminopeptidase-like enzyme. The gene for DSIP has not been isolated in rabbits, and no receptor or precursor peptide has been identified. A 2006 review in the Journal of Neurochemistry was titled "a still unresolved riddle." Twenty years later, the description still fits.

What the FDA Did on July 24, 2026

The FDA's Pharmacy Compounding Advisory Committee (PCAC) met July 23 and 24, 2026, to consider seven peptide bulk drug substances for the 503A Bulks List. On July 24, the committee voted 6 to 7 against recommending emideltide, with one abstention. It was the only one of the seven peptides rejected. The committee backed the other six.

FDA staff recommended against all seven peptides reviewed that week. FDA reviewer Katie Park stated there was "a lack of safety and efficacy data to support using emideltide for treating insomnia, narcolepsy and opioid use disorder" (RAPS). FDA briefing materials separately noted that the peptide is not adequately characterized, with potential for impurities from incomplete coupling reactions. Committee member Kevin Zacharoff, explaining his vote against, said: "As a clinician, it's impossible for me not to take FDA's recommendations to heart with respect to safety and efficacy data."

Two things this does not mean. First, an advisory committee recommendation is not FDA approval. It is a recommendation. FDA must complete formal rulemaking and is not required to follow the committee. Second, the removal of twelve peptides from Category 2 in April 2026 did not authorize compounding, selling, or prescribing anything. It only made advisory committee review possible. None of the seven peptides reviewed in July 2026 is an FDA-approved drug.

The Human Trial Record on DSIP Peptide and Sleep

The human evidence base is small, old, and mixed. Every study described below was conducted between roughly 1984 and 1992, with sample sizes in the range of 6 to 16. No modern controlled trial exists.

1984: An open study in seven patients. A short open-label series in seven patients with severe insomnia, with no control group and no placebo. The researchers reported that sleep was normalized in all but one case for follow-up periods of 3 to 7 months, with reported improvement in daytime mood and performance. This is the result most commonly cited in online discussions of DSIP. It was uncontrolled, included seven people, and is now over forty years old.

1984 and 1987: Additional reports. A 1984 clinical trial and a 1987 report in severe chronic insomnia also appeared in the European Neurology literature. Sample sizes for these reports were not independently verified for this article, so no numeric results are attached here.

1992: The best-controlled trial. Bes and colleagues published the only double-blind study, a matched-pairs parallel-groups design over five consecutive laboratory nights in 16 chronic insomnia patients (Neuropsychobiology, 1992). Results showed higher sleep efficiency and shorter sleep latency with DSIP compared to placebo on objective measures.

Then the authors qualified what they found.

The Trial Everyone Cites, and What Its Authors Concluded

The Bes 1992 trial is the study that appears in nearly every write-up about DSIP. What rarely appears is the authors' own assessment. They reported that the significant effects were weak and could in part be due to an incidental change in the placebo group. Subjective sleep quality showed no change.

Their exact conclusion: "As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit." (Neuropsychobiology, 1992;26(4):193-197)

That sentence is worth reading twice. The best-controlled human study in the record found weak objective effects, no subjective improvement, and its own authors concluded the result was unlikely to matter clinically. The online discussion of DSIP almost never includes this sentence.

Why the Evidence Never Advanced

Preclinical slow-wave sleep findings were reported in several animal species but not reproduced in all of them. The 15-minute in vitro half-life created formulation challenges. No receptor has been identified. And the 2006 Kovalzon review noted that the link between DSIP and sleep has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein, and possible related receptor.

Thirty-four years after the last controlled trial, there is still no modern replication. The FDA staff briefing materials for the July 2026 meeting reflected exactly this gap: every study in the record dates to the 1980s or early 1990s.

What "Not FDA Approved" Actually Means Here

DSIP is not approved by the FDA for any indication. It is also not a dietary supplement. Under the Dietary Supplement Health and Education Act (DSHEA), synthetic peptides are not dietary ingredients unless they occur naturally in food, and supplements must be ingested. Products commonly carry labels like "research use only" or "not for human consumption." Because these products sit outside both drug approval and the supplement definition, nobody verifies what is in the container.

An FDA advisory panel voted 6 to 7 against recommending emideltide. That is not a ban. It is not approval. It is a recommendation that sits inside a longer rulemaking process, and the compound remains unapproved.

What This Article Deliberately Does Not Cover

No dosing information, no sourcing, no administration details, no vendors, no protocols. The reason is straightforward: the safety data that would make those questions answerable does not exist. FDA reviewers specifically flagged missing data on impurities, aggregates, and endotoxins in the emideltide docket. Describing how to use a substance with this evidence profile would be irresponsible, and this page will not do it.

Conclusion

If the reason you searched for the DSIP peptide was a desire for deeper or longer sleep, the interventions with controlled human evidence behind them are less exotic but better supported.

Consistent sleep timing. Protecting the first third of the night, when slow-wave sleep concentrates, starts with going to bed early enough and at the same time. A 2022 randomized controlled trial of sleep restriction therapy in adults with insomnia disorder found that the approach increased NREM delta power, a direct measure of deep sleep pressure (Maurer et al., SLEEP, 2022).

Warm bathing 1 to 2 hours before bed. A systematic review of 17 studies found that passive body heating at 40 to 42.5°C for as little as 10 minutes shortened sleep onset latency by roughly 36%, about 10 minutes on average (Haghayegh et al., Sleep Medicine Reviews, 2019).

Keeping total daily caffeine modest. A systematic review and meta-analysis of 24 studies confirmed caffeine's dose-dependent effects on sleep architecture (Gardiner et al., Sleep Medicine Reviews, 2023).

Cognitive behavioral therapy for insomnia (CBT-I). For insomnia that persists, CBT-I has more supporting evidence than anything else discussed on this page, or any peptide page. Sleep problems that last weeks deserve a clinician.

For a fuller breakdown of these levers, see what actually increases deep sleep. A printable version lives in the sleep hygiene checklist. And for context on what short sleep actually costs, measured in cognitive and physiological terms, see sleep deprivation's effects on the brain.

Frequently Asked Questions

Does DSIP work for sleep?

The human evidence is limited and old. The only double-blind trial, in 16 chronic insomnia patients in 1992, found weak objective improvements in sleep efficiency and sleep latency but no change in subjective sleep quality. The authors concluded that DSIP "is not likely to be of major therapeutic benefit." A 1984 open study in seven patients reported normalized sleep, but it had no control group. No modern controlled trial has been conducted.

Is DSIP the same thing as emideltide?

Yes. The FDA and its advisory committees use the name emideltide. Consumer-facing content, online forums, and grey-market product labels use DSIP (delta sleep-inducing peptide). They refer to the same nonapeptide, first isolated from rabbit cerebral venous blood in the 1970s.

Is DSIP FDA approved?

No. DSIP is not approved by the FDA for any indication. It is also not classified as a dietary supplement under federal law because synthetic peptides do not meet the dietary-ingredient definition under DSHEA unless they occur naturally in food.

What did the FDA panel decide in July 2026?

The FDA's Pharmacy Compounding Advisory Committee voted 6 to 7, with one abstention, against recommending emideltide (DSIP) for the 503A Bulks List on July 24, 2026. It was the only one of seven peptides reviewed that week to be rejected. This recommendation is not a final FDA decision; the agency must complete its own rulemaking process.

Are there any modern studies on DSIP?

No. The human trial record dates entirely to the 1980s and early 1990s, with sample sizes ranging from 6 to 16 participants. A 2006 review in the Journal of Neurochemistry described the peptide as "a still unresolved riddle," and no controlled human trial has been published since 1992.

What actually increases deep sleep instead?

The interventions with the strongest controlled evidence include consistent sleep timing, passive body heating 1 to 2 hours before bed, moderate caffeine intake, and cognitive behavioral therapy for insomnia (CBT-I). For persistent sleep problems, understanding how adenosine and sleep pressure function may be more useful than any single compound, and a clinician is the right next step.

Caffeine Timing Is the Legal, Boring Lever That Actually Has Data

The article above ends where most practical sleep hygiene begins: consistent timing and managing your stimulant load. That is not glamorous, but it is backed by decades of controlled research rather than a handful of small trials from the 1980s.

Roon is a zero sugar sublingual caffeine pouch (80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine, 5 mg theacrine) designed for a 6 to 8 hour alertness window during work. It is not a sleep product and makes no sleep claim. The relevant trade-off is straightforward: stop at least 8 hours before bed so the caffeine clears before your sleep window opens. Subscriptions start from $9.16 per tin, or as little as $0.61 per pouch. A one-time 4-tin order is $15.00 per tin.

For persistent sleep problems, CBT-I and a clinician remain the evidence-backed path. Roon just keeps the caffeine side of the equation honest and time-bound.

Written by Roon Team